Therapy of Alzheimer's disease: An update

African Journal of Pharmacy and Pharmacology

Volumn 4, Issue 6, 2010, Pages 408-421

  Upadhyaya, Prerna ^a   Seth, Vikas ^a   Ahmad, Mushtaq ^a  

^a GANDHI MEDICAL COLLEGE   (India)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Gamma secretase inhibitors; Neuroprotective agents; Therapy of alzheimer's disease

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ANTIOXIDANT; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; DEFEROXAMINE; DIMEBON; DONEPEZIL; EVP 6124; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MEMANTINE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RIVASTIGMINE; SELEGILINE; SEMAGACESTAT; SEROTONIN ANTAGONIST; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CEREBROVASCULAR ACCIDENT; CHEST INFECTION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; DEPRESSION; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EXERCISE; HUMAN; LIVER TOXICITY; MAINTENANCE THERAPY; MEMORY DISORDER; MENTAL DISEASE; METABOLIC SYNDROME X; MUSIC THERAPY; NAUSEA AND VOMITING; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOSIS; RECOMMENDED DRUG DOSE; SENILE PLAQUE; SYNCOPE;

EID: 77954680048     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (167)

1. A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease (CONNECTION). Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00675623. Accessed on 15th June 2010.
2. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 54: 588-93.
3. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. J. Am. Med. Assoc., 289: 2819-26. provide other names, et al is not allowed in reference
4. Alzheimer's disease in India. Available from: www.alzheimerdiseaseinindia.blogspot.com/.../rise-of-alzheimersdisease-cases-html-. Accessed on 15th June 2010.
5. Alzheimer's disease in India. Available from: www.alzheimerdiseaseinindia.blogspot.com/.../demographictransition-in-india-how-to.html-. Accessed on 15th June 2010.
6. Alzheimer's Disease Vaccine Trial Suspended on Safety Concern. Medpage Today. 2008-04-18. http://www.medpagetoday.com/MeetingCoverage/AAN/tb/9165. Accessed on 14th June 2010.
7. Alzheimer's Disease: FDA's Role In New Product Development. Available from: www.fda.gov/NewsEvents/Testimony/ucm110879.htm. Accessed on 14th June 2010.
8. Avila J, Lucas JJ, Pérez M, Hernández (2004). Role of Tau protein in both physiological and pathological conditions. Physiol. Rev., 84: 361-84.
9. Bains J, Birks JS, Dening TD (2007). Antidepressants for treating depression in dementia, Cochrane Database Syst. Rev., 3.
10. Ballard C, Howard R (2006). Neuroleptic drugs in dementia: benefits and harm, Nat. Rev. Neurosci., 7: 492-500.
11. Ballard C, Lana MM, Theodoulou M, et al, Douglas S, McShane R, Jacoby R et al (2008). A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial), PLoS Med., 5: e76.
12. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A et al (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial, BMJ, 330: 874-7.
13. Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease/ Apo_e4 non-carriers. Clinical Trial. US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00574132. Accessed on 14th June 2010.
14. Birks J, Grimly EJ, Lakovidou V, Tsolaki M, Holt FE (2009). Rivasigmine for Alzheimer disease. Cochrane Database Syst Rev. 15: CD001191. therapy and Alzheimer's disease. Am. Acad. Neurol., 48: S27-S35.
15. Birks J, Harvey RJ (2006). Donepezil for dementia due to Alzheimer disease. Cochrane database Syst. Rev., 25: CD001190.
16. Braak H, Braak E (1994). Pathology of Alzheimer's disease. In: Calne D, ed. Neurodegenrative Diseases. Philadelphia: Saunders, 585-614.
17. Brenner DE, Kukull WA, Stergachis A, Van Belle G, Bowen JD, McCormick WC, et al (1994). Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study. Am. J. Epidemiol., 140: 262-67.
18. Brinton RD (2004). Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS Drugs. 18: 405-22.
19. Brion JP (1998). Neurofibrillary tangles and Alzheimer's disease. Eur. Neurol., 40: 130-40.
20. Burns A, Murphy D. (1996). Protection against Alzheimer's disease? [Commentary]. Lancet., 348: 420-421.
21. Bush AI, Pettingell WH, Paradis MD, and Tanze RE (1994). Modulation of a beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem., 269: 12152-12158.
22. Camps P., Munoz-Torrero D (2002). Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini. Rev. Med. Chem., 2: 11-25.
23. Caring for the Alzheimer's disease patient. Geriatric mental health foundation. (Accessed on 7th May 2010) Available from: http://www.gmhfonline.org/gmhf/consumer/factsheets/caring_alzheimer_diseasecg.html.
24. Chandra V, Bharucha NE, Schoenberg BS (1986). Conditions associated with Alzheimer's disease at death: case-control study. Neurology, 36: 209-211.
25. Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, Dekosky ST (1998). Prevalence of Alzheimer disease and other dementias in rural India. Neurol., 51: 1000-8.
26. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM (2000). Expression of PPARs in human astrocytic cells: PPAR gamma agonists as induces of apoptosis. J Neurosci Res. 61: 67-74.
27. Chun W, Johnson GV (2007). The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci., 12: 733-56.
28. Clinical Trials: Found 801 studies with search of: alzheimer. (Accessed on 12th June 2010). Available from: http://www.clinicaltrials.gov/ct2/results?term=alzheimer.
29. Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease. Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00478205. Accessed on 15th June 2010.
30. Corey-Bloom J, Anand R, Veach J (1998). for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (Rivastigmine Tartarate), a new Acetyl cholinesterase inhibitor, in
31. Cornett CR, Markesbery WR, Ehmann WD (1998). Imbalance of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology. 19: 339-345.
32. Coyle J, Kershaw P (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatr., 49: 289-99.
33. Crapper-Malachlan DR, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kalow W (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 337: 1304-1308.
34. Cummings J, Lefevre G, Small G, Appel-Dingemanse S (2007). Pharmacokinetic rationale for the rivastigmine patch. Neurol., 69: S10-3.
35. Cummings JL (2004). Alzheimer's disease. N Engl J Med. 351: 56-67.
36. Cummings JL, Schneider E, Tariot PN, Graham SM (2006). Behavioural effects of memantine in Alzheimer's disease patients receiving donepezil treatment, Neurol., 67: 57-63.
37. Danysz W, Parsons CG (2003). The NMDA receptor antagonist Memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: a preclinical evidence. Int. J. Geriatr. Psychiatry, 18: S23-32.
38. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W (2010). Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease: Rationale and Current Evidence. Drugs. 70: 513-528.
39. Dolga AM, Granic I, Nijholt IM, Nyakas C, VanDer Zee EA, Luiten PGM (2009). Pretreatment with Lovastatin prevents N-methyl-D-Aspartate induced neurodegeneration in the magnocellular Nucleus Basalis and Behavioral dysfunction. J. Alzheimer. Dis., 17: 2.
40. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION). Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00905372. Accessed on 15th June 2010.
41. Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION2). Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00904683. Accessed on 15th June 2010.
42. Effect of LY450139 on the Long Term Progression of Alzheimer's Disease. Available from: http://www.clinicaltrials.gov/show/NCT00594568. (Accessed on 12th June 2010).
43. Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo (IDENTITY-2). Available from: http://www.clinicaltrials.gov/show/NCT00762411. (Accessed on 12th June 2010)
44. Evin G, Sernee MF, Masters CL (2006). Inhibition of gamma secretase as a therapeutic intervention for Alzheimer's disease: Prospects, limitations and strategies. CNS drug. 20: 351-72.
45. Farlow MR, Tariot P, Grossberg GT, Gergel I, Grahm S, Jin J (2003). Menantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer Disease. Neurology, 60: A412.
46. FDA ALERT: Galantamine hydrobromide (marketed as Razadyne, formerly Reminyl) - Healthcare Professional Sheet. Postmarket Drug Safety Information for Patients and Providers. Food and Drug Administration. May 2005. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126138.pdf. Accessed on 14th June 2010.
47. FDA NEWS RELEASE- For Immediate Release: Dec. 15, 2009 FDA Approves Generic Aricept to Treat Dementia Related to Alzheimer's Disease. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm194173.htm (Accessed on 12th June 2010).
48. Finch CE, Longo V, Miyao A, et al (2001). Inflammation in Alzheimer's disease. In: Chesselet M-F, ed. Molecular mechanisms of neurodegenerative diseases. Totowa,N.J.: Humana Press. 87-110.
49. Finkel SI (2004). Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther., 26: 980-990.
50. Flynn BL, Theesen KA (1999). Pharmacologic management of Alzheimer's disease, Part III: Nonsteroidal anti-inflammatory drugsemerging protective evidence? Ann. Pharmacother., 33: 840-849.
51. Frank B, Gupta S (2005). A review of antioxidants and Alzheimer's disease. Ann. Clin. Psych., 17: 269-86.
52. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M et al (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative study. Alzheimer Dis. Assoc. Disord., 11: S33-S39.
53. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P et al (2002). Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease, Int Psychogeriatrics.14: 389-404.
54. Gauthier S, Wirth Y, Möbius HJ (2005). Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies, Int. J. Geriatric Psych., 20: 459-64.
55. Giacobini E (1994). Therapy for Alzheimer disease. Symptomatic or Neuroprotective. Mol Neurobiol., 9: 115-8.
56. Griffin WS (2008). Perispinal etanercept: potential as an Alzheimer therapeutic. J. Neuroinfl., 5: 3.
57. Grundman M, Grundman M, Delaney P (2002). Antioxidant strategies for Alzheimer disease. Proc Nutr Soc. 61: 191-202.
58. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297: 353-6. (Erratum, Science 2002;297:2209.)
59. Harrington C, Rickard JE, Horsley D, et al. (2008). Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimer's and Dementia (Alzheimer's Association) 4: T120-T121.
60. Hawkes CA, McLaurin J (2007). Immunotherapy as treatment for Alzheimer's disease. Expert Rev. Neurother., 7: 1535-48.
61. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003). Alzheimer disease in the US population: prevalence estimates using the 2000 Census. Arch Neurol., 60: 1119-22.
62. Henderson VW (2006). Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neurosci., 138: 1031-9.
63. Henderson VW (2007). Alzheimer's disease and other neurological disorders. Climacteric, 10: 92-6.
64. Henderson VW, Paganini-Hill A, Miller BL, Elble BL, Reyes PF, Shoupe D, et al (2000). Estrogen for AD in women-randomized, double blind placebo controlled trial. Neurol., 54: 295-301.
65. Henderson, V.W. (1997). The epidemiology of estrogen replacement therapy and Alzheimer's disease. Am. Acad. Neurol., 48: S27-S35.
66. Heneka MT, Sastre M, Ozimek LD, hanke A, Dewachter I, Kuiperi C (2005). Acute treatment with the PPAR agonist pioglitazone and ibuprofen reduces glial inflammation and Aß1-42 levels in APPV717I transgenic mice. Brain. 128: 1442-53.
67. Heneka MT, Sastre M, Ozimek LD, hanke A, Dewachter I, Kuiperi C (2005). Acute treatment with the PPAR agonist pioglitazone and ibuprofen reduces glial inflammation and Aß1-42 levels in APPV717I transgenic mice. Brain. 128: 1442-53.
68. Hernández F, Avila J (2007). Tauopathies. Cell. Mol. Life Sci., 64: 2219-33.
69. Hollosi M, Shen ZM, Perczel A, Fasman GD (1994). Stable Intrachain and interchain complexes of neurofilament peptides: a putative link between AI+++ and Alzheimer's disease. Proc Natl Acad Sci USA. 91: between AI+++ and Alzheimer's disease. Proc Natl Acad Sci USA. 91: 4902-4906.
70. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease, Neurol. 63: 214-19.
71. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R (2007). Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 357:1382-1392.
72. Jann MW (2000). Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 20: 1-12.
73. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A (1997). A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. Neurology. 48: 1517-1521.
74. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994). A 30 week randomized controlled trial of high dose Tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc., 271: 985-91.
75. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N (2001). Practice parameter: diagnosis of dementia (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56: 1143-53.
76. Kosasa T, Kuriya Y, Matsui K, Yamanish Y (2000). Inhibitory effect of orally administered Donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease on cholinesterase activity in rats. Eur. J. Pharmacol., 389: 173-9.
77. Krall WJ, Sramek JJ, Cutler NR (1999). Cholinesterase Inhibitors: a therapeutic strategy for Alzheimer's disease. Ann. Pharmacother. 33: 441-50.
78. Landreth G (2007). Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr. Alzheimer Res., 4: 159-64.
79. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJE (2002). New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem., 277: 42881-90.
80. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997). A placebo controlled, double blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb study group. J. Am. Med. Assoc., 278: 1327-32.
81. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A et al (2007). Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology, 69: 878-85.
82. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci., 20: 5709-14
83. Lipton SA (2004). Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis., 6: S61-74.
84. Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA (2005). Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochem. Biophys. Acta. 1741: 246-52.
85. Lonergan ET, Luxenberg J (2007). Valproate preparations for agitation in dementia, Cochrane Database Syst. Rev., 3.
86. Long-term Safety and Tolerability of AFFITOPE AD02. Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00711321. Accessed on 15th June 2010.
87. Magenheim MJ (1998). Preventive health maintenance. In: Duthie EH Jr, Katz PR, eds. Practice of Geriatrics. 3rd ed. Philadelphia: W.B. Saunders: 115-29.
88. Mancuso C, Bates TE, Bulterfield DA, Calafato S, Cornelius C, Lorenzo AD et al (2007). Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs. 16: 1921-31.
89. McGeer PL, Schulzer M, McGeer EG (1996). Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology, 47: 425-432.
90. McGuinness B, Craig D, Bullock R, Passmore P (2009). Statins for the prevention of dementia. Cochrane Database of Systematic Reviews, Issue 2.
91. McShane R, Areosa Sastre A, Minakaran N (2007). Memantine for dementia, Cochrane Database Syst. Rev., 3.
92. Mega MS, Cummings JL, Fiorello T, Gornbein J (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology. 46: 130-5.
93. Mendez MF (2006). The accurate diagnosis of early-onset dementia. Intl J Psych Med. 36: 401-12.
94. Mental health and substance abuse. Alzheimer's disease: The brain killer. Available from: http://www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8068.htm.Accessed on 15th June 2010.
95. Mutter J, Naumann J, Sadaghiani C, Schneider R, Walach H (2004). Alzheimer disease: Mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuroendocrinol. Lett., 25: 331-39.
96. Nyth AL, Gottfries CG (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders, Br. J. Psych., 157: 894-901.
97. Oken BS, Storzbach DM, Kaye JA (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 55: 1409-15.
98. Opie J, Rosewarne R, O'Connor DW (1999). The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J. Psych. 33: 789-99.
99. Ott BR, Owens NJ (1998). Complementary and alternative medicines for Alzheimer's disease. J. Geriatr. Psychiatry Neurol., 11: 163-73.
100. Oyama Y, Chikahisa L, Ueha T, Kanemaru K, Noda K (1996). Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res., 412: 349-352.
101. Paganini-Hill A, Henderson VW (1994). Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol., 140: 256-61.
102. Paganini-Hill A, Henderson VW (1996). Estrogen replacement therapy and risk of Alzheimer's disease. Arch In. Med. 156: 2213-2217.
103. Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ (2000). Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients. Neurobiol. Aging. 21: 11-7.
104. Parsons CG, Danysz W, Quack G (1998). Memantine is a clinically well tolerated NMDA receptor antagonist- a review of preclinical data. Neuropharmacology, 38: 735-67.
105. patients with mild to moderate severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol., 1: 55-6.
106. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR (2007). A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia, Am J Geriatric Psych.;15:942-52.
107. Raskind MA, Peskind ER, Wessel T, Yuan W (2000). Galantamine in AD: a 6 month randomized, placebo controlled trial with a 6 month extension. Neurol., 54: 2261-8.
108. Reavill C and Rogers DC (2001). The therapeutic potential of 5-HT6 receptor antagonist. Curr. Opin. Invest. Drugs. 2: 104-109.
109. Regan CM, Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ (2003). The 5 HT6 receptor antagonist SB-271046 and SB-399885 increase basal and learning induced NCAM-polysialylation in the rat dentate gyrus. Society for Neuroscience, 33rd Annual Meeting, New Orleans, USA (Abstract no. 835.21).
110. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003). Memantine in moderate to severe Alzheimer's disease. N Engl. J. Med., 348: 1333-41.
111. Ren K, King MA, Liu J, Siemann J, Altman M, Meyers C (2007). The alpha 7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloidoverexpressing transgenic mice. Neuroscience. 148: 230-7.
112. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998). Donepezil improves cognition and global function in Alzheimer's disease: a 15 week, double blind, placebo controlled study. Arch Int. Med., 158: 1021-31.
113. Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease. Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01073228. Accessed on 15th June 2010.
114. Safety Labeling Changes Approved By FDA Center for Drug Evaluation Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). MedWatch, The FDA Safety Information and Adverse Event Reporting Program. Food and Drug Administration. April 2006. Archived from the original on 2007-10-09. http://web.archive.org/web/20071009145003/http://www.fda.gov/medwatch/safety/2006/apr06.htm. Accessed on 14th June 2010.
115. Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment. Clinical Trial. US National Institutes of Health. Available from: on http://clinicaltrials.gov/ct2/show/NCT00422981. Accessed on 14th June 2010.
116. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M (1997). A controlled trial of selegiline, alpha tocopherol, or both as treatment for Alzheimer disease. N Engl. J. Med., 336: 1216-22.
117. Sapronov NS, Fedotova YO, Kuznetsova NN (2006). Antiamnestic effect of _7-nicotinic receptor agonist RJR-2403 in middle-aged ovariectomized rats with Alzheimer type dementia. Bull. Exp. Biol. Med., 142: 700-702.
118. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2009). Efficacy of PPAR gamma agonist Piogitazone in mild Alzheimer's disease. Neurobiol Aging. (Epub ahead of print). doi:10.1016/j.neurobiolaging.2009.10.009
119. Schaff-hauser H, mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, Mckenna BA (2009). Dimebolin is a 5HT6 antagonist with acute cognition enhancing activities. Biochem. Pharmacol., 78: 1035-42.
120. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N (1999). A double-blind, placebocontrolled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology, 53: 97-201.
121. Schneider LS, Dagerman K, Insel PS (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials, Am. J. Ger. Psych. 14:191-210.
122. Schneider LS, Dagerman KS, Insel P (2005). Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Metaanalysis of Randomized Placebo-Controlled Trials, JAMA. 294:1934-43.
123. Schneider LS, Pollock VE, Lyness SA (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. J. Am. Geriatr. Soc., 38:553-563.
124. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS (2006). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease, N Engl. J. Med., 355:1525-38.
125. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Hsiao JK (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am. J. Geriatr. Psychiatry, 9:346-360.
126. Semagacestat- Gamma Secretase Inhibitor for Alzheimer's Disease Semagacestat- Gamma Secretase Inhibitor for Alzheimer's Disease (AD). (Accessed on 7th May 2010). Available from: http://www.drugdevelopment-technology.com/projects/semagacestat
127. Shumaker SA, Legault C, Rapp SR (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. J. Am. Med. Assoc., 289: 2651-62.
128. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P (2006). Effects of a Gamma secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology, 6: 602-4.
129. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W et al (2001). Positron emission tomography in evaluation of dementia: Regional brain metabolism and long term outcome. J. Am. Med. Assoc., 286: 2120-7.
130. Sink KM, Holden KF, Yaffe K (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J. Am. Med. Assoc., 293:596-608.
131. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH (1997). Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association of Geriatric psychiatry, the Alzheimer's Association and the American Geriatric Society. J. Am. Med. Assoc., 278: 1363-71.
132. Solomon B (2007). Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 16: 819-28.
133. Steele LS, Glazier RH (1999). Is donepezil effective for treating Alzheimer's disease?. Can. Fam. Physician, 45: 917-9.
134. Stewart WF, Kawas C, Corrada M, Metter EJ (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48: 626-632.
135. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN et al (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch Gen. Psych., 57: 968-976.
136. Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects. Clinical Trial. US National Institutes of Health. 2008-03-11. http://www.clinicaltrials.gov/ct/show/NCT00498602. Accessed on 14th June 2010.
137. Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects With Alzheimer's Disease. US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00479557. Accessed on 14th June 2010.
138. Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease. Clinical Trial. US National Institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT00471211. Accessed on 14th June 2010.
139. Suh YH (1997). An etiological role of amyloidogenic carboxyl-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J. Neurochem., 68: 1781-91.
140. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME (1997). A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia, Am. J. Geriatric Psych. 5:60-69.
141. Support for Alzheimer's and Dementia Caregivers. www.helpguide.org. (Accessed on 7th May 2010) Available from: http://www.helpguide.org/elder/alzheimers_disease_dementia_support_caregiver.htm.
142. Tabert MH, Liu X, Doty RL, Serby M, Zamora D, Pelton GH (2005). A 10-item smell identification scale related to risk for Alzheimer's disease. Ann. Neurol., 58: 155-160.
143. Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B (1996). Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet, 348: 429-32.
144. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia, Am. J. Psych., 155:54-61.
145. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J. Am. Med. Assoc., 291: 317-24.
146. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE (2000). Treatment of agitation in AD: a randomized, placebocontrolled clinical trial, Neurol. 55: 1271-8.
147. Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J (2007). Systematic review of information and support interventions for caregivers of people with dementia. BMC Geriatr. 7: 18.
148. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 62: 1984-89.
149. Tombaugh TN, McIntyre NJ (1992). The mini-mental state examination: a comprehensive review. J. Am. Geriatr. Soc., 40: 922-35.
150. Tomita T, Iwatsubo T (2006). Gamma secretase as a therapeutic target for treatment of Alzheimer disease. Curr Pharm Des. 12: 661-70.
151. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K (2003). Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease. J. Am. Med. Assoc., 289:210-216.
152. Vlad SC, Miller DR, Kowall NW, Felson DT (2008). Protective effects of NSAIDs on the development of Alzheimer's disease. Neurology, 70: 1672-77.
153. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M (2007). Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol.. 14: e1-26.
154. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A (2007). Donepezil in Alzheimer disease: What to expect after 3 years of treatment in a routine clinical setting. Demnt Geriatr Cogn Disord. 23: 150-60.
155. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH (2005). Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Eng. J. Med., 353:2335-2341.
156. Watkins PB, Zimmerman HJ, Knapp MJ, Garcon SI, Lewis KW (1994). Hepatotoxic effect of Tacrine administration in patients with Alzheimer's disease. J. Am. Med. Assoc., 271: 992-8.
157. Wilcock GK, Ballard CG, Cooper JA, Loft H (2008). Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies, J. Clin. Psych., 69: 341-8.
158. Willson TM, Brown PJ, Sternbach DD, Henke BR (2004). The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 43: 527-550.
159. Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, Lane R (2007). "IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease". Neurol, 69: S14-22.
160. Wischik CM, Bentham P, Wischik DJ, Seng KM (2008). Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's and Dementia (Alzheimer's Association). 4: T167.
161. Woodhouse A, Dickson TC, Vickers JC (2007). Vaccination strategies for Alzheimer's disease: A new hope?. Drugs Aging. 24: 107-19.
162. Xiong G, Doraiswamy PM (2005). Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics, 60 (6): 22-6.
163. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K (2002). Patient and caregiver characteristics and nursing home
164. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K (2002). Patient and caregiver characteristics and nursing home placement in patients with dementia. J. Am. Med. Assoc., 287: 2090-7.
165. Yaffe K, Sawaya G, Lieberburg I, Grady D (1998). Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Med. Assoc., 279: 688-695.
166. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL (2003). Antiinflammatory drug therapy alters beta Amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neursci., 23: 7504-9.
167. Zec RF, Burkett NR (2008). Non Pharmacological and Pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. NeuroRehab., 23: 425-38.